Overview

Ribavirin Loading Dose or Priming and Concentration Targeting for HCV Genotype 1

Status:
Completed
Trial end date:
2014-09-01
Target enrollment:
Participant gender:
Summary
This is a randomized, open-label, parallel group, multicenter pilot study evaluating the efficacy and safety of alternative dosing of ribavirin vs. standard of care dosing in combination with peginterferon alpha-2a in interferon naïve patients with chronic hepatitis c genotype 1 infection.
Phase:
Phase 3
Details
Lead Sponsor:
Göteborg University
Collaborators:
Roche Pharma AG
The Swedish Research Council
Treatments:
Ribavirin